TARS - CIK 0001819790
Tarsus Pharmaceuticals, Inc. (TARS) reported net income of -$66.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$66.00M | +43.1% |
| FY 2024 | -$116.00M | +14.7% |
| FY 2023 | -$136.00M | -119.0% |
| FY 2022 | -$62.09M | -349.1% |
| FY 2021 | -$13.83M | +48.4% |
| FY 2020 | -$26.81M | -474.1% |
| FY 2019 | -$4.67M | -254.1% |
| FY 2018 | -$1.32M | - |
Tarsus Pharmaceuticals, Inc. (TARS) reported net income of -$66.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, Tarsus Pharmaceuticals, Inc.'s net income declined from -$1.32M to -$66.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.